AlphAIAlphAI — Financial news for AI agents
fool.comSEP 22 min read$ARGX

Argenx Has Delivered 18 Consecutive Quarters of Sales Growth -- but Is the Biotech Stock Still Underrated?

Argenx reported 18 consecutive quarters of revenue growth, with Q2 2026 sales up 60% year-over-year. Its therapies Vyvgart and Vyvgart Hytrulo are driving growth, with expanding operating margins. The company expects further growth from new indications and pipeline developments. Analysts rate it a buy, with a 14% upside target.

Original reporting
fool.com
Published Sep 2, 2026, 9:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 2, 2026, 9:24 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Argenx Has Delivered 18 Consecutive Quarters of Sales Growth -- but Is the Biotech Stock Still Underrated? — source image
Source · fool.com
Decision brief

The 30-second read

$ARGXBullishMed
01

Why it matters

The new trial data adds a high‑impact catalyst that could accelerate revenue growth and justify higher valuation multiples.

02

Market read

Positive trial results for a mid‑cap biotech can trigger notable price moves and influence sector sentiment.

03

What to watch

Regulatory timelines and reimbursement uncertainty for the new indication could delay commercial upside.

Relevance 8/10Novelty 8/10Timing: recent clinical win reported early September

Background

Argenx has delivered 18 quarters of revenue growth, driven by Vyvgart and its Hytrulo formulation, and is expanding its pipeline with multiple upcoming studies.

Company-level read

Ticker impact

$ARGXBullishHigh confidence
Context

Argenx announced positive late‑stage trial results for Vyvgart Hytrulo in autoimmune myositis, a new clinical win.

Expected impact

Potential short‑term price rally of 5‑10% as investors price in the new indication.

Evidence & confidence

Clinical success in a rare disease adds a multibillion‑dollar opportunity and validates the platform, which historically moves biotech stocks sharply.

Market effects

Sector

Strengthens the autoimmune‑biologics sector and may boost peers with similar platforms.

Regional

U.S. biotech market gains confidence in late‑stage trial pipelines.

Global

Highlights the potential of hybrid biologic‑delivery technologies worldwide.

Counterpoint

What could challenge this read

The stock may already be priced for growth; further data could disappoint, leading to a pull‑back.

Key entities

  • Company
    Argenx

    Biotech firm developing Vyvgart and pipeline candidates.

  • Product
    Vyvgart Hytrulo

    Hybrid biologic targeting severe autoimmune diseases.

Read at source← All news

Also covered by

1 outlet

Related articles

OCT 23
$ARGXHighAI 8/10

argenx (ARGX) Q3 2026 Earnings Call Transcript

argenx (ARGX) reported Q3 2026 revenue of $1.7B, up 54% YoY. The company anticipates 5 potential drug launches in 2027, including VYVGART for new indications and empasiprubart for MMN. argenx also plans increased R&D and SG&A expenses for 2026, totaling $4B, driven by pipeline advancements and the Forte acquisition.

finance.yahoo.com3 min
OCT 22
Med

argenx SE (ARGNF) (Q3 2026) Earnings Call Highlights: VYVGART Sales Surge 54%

argenx SE (ARGNF) reported a 54% surge in VYVGART sales. The company increased 2026 OpEx guidance to $4B, with half attributed to the Forte acquisition. Management expects growth in MG and CIDP revenues, with additional indications driving Vision 2030. Potential 2027 launches include MMN, pending positive IMPASSION data. The FDA requested an additional dermatomyositis trial, and management remains confident in delivering Vision 2030.

finance.yahoo.com3 min
OCT 22
$ARGXHighAI 8/10

argenx SE (ARGNF) (Q3 2026) Earnings Call Highlights: VYVGART Sa

argenx SE reported Q3 2026 product net sales of $1.7B, up 54% YoY. VYVGART's seronegative MG launch saw strong access. Phase 3 ALKIVIA results support autoimmune myositis expansion. Operating expenses are rising to $4B, up 45% YoY, due to acquisitions and pipeline investments. The FDA required an additional trial for dermatomyositis, delaying approval. Empasiprubart's Phase 3 study in MMN is expected in December. The company did not provide formal revenue guidance, citing uncertainty.

gurufocus.com2 min
OCT 22
$ARGXMedAI 8/10

Jefferies reiterates argenx stock Buy rating after Q3 beat

Jefferies reiterated a Buy rating and $1,200 price target for argenx SE (ARGX) after its Q3 results. The company reported Vyvgart revenues of $1.7B, a 5% beat, and EPS of $7.80, in line with estimates. Operating expenses were higher due to the Forte deal. Analysts expect data readouts and revenue growth to drive future performance, with projections of $6.5B in FY2026 revenues. Other analysts have mixed price target adjustments.

investing.com2 min